You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
復宏漢霖(02696.HK)與FBD就HCB101訂立許可協議

格隆匯6月30日丨復宏漢霖(02696.HK)發佈公告,於2025年6月30日,公司與FBD Biologics Limited訂立一份許可協議,據此,FBD同意授予公司一項獨家許可,以於領域及於公司許可區域內開發、生產、商業化或以其他方式利用HCB101(許可分子)和以其作爲原料藥的藥品。

公司須向FBD支付:(a) 首付款10百萬美元;(b) 開發及監管里程碑付款合計不超過49百萬美元,基於許可產品的有關里程碑達成情況;(c) 商業里程碑付款合計不超過1.43億美元,基於許可產品的有關里程碑達成情況;及(d) 以年度淨銷售額一至兩位數百分比計的特許權使用費,基於許可產品於公司許可區域內的年度淨銷售額水平。根據許可協議約定,特許權使用費在雙方協商一致的特定情況下可能會有所減免。

HCB101是由FBD內部指定的一種SIRPα-Fc融合蛋白,由人信號調節蛋白α(SIRPα)的工程化IgV結構域與IgG4 Fc融合而成。HCB101能夠以高親和力與CD47結合,抑制野生型SIRPα的結合,並增強巨噬細胞對腫瘤細胞的吞噬作用。許可產品目前處於1b/2a期臨牀試驗中。

FBD於2021年在香港註冊成立,其控股股東HanchorBio Inc.系一家專注於腫瘤免疫治療領域的新藥研發的生物技術公司。HanchorBio Inc.董事長兼首席執行官爲Scott Shi-Kau Liu博士。

許可分子爲靶向CD47的SIRPα-Fc融合蛋白,在早期臨牀試驗中已展現出對腫瘤患者(包括實體瘤)的初步療效,截止目前全球範圍內尚未有同靶點藥物獲批上市,許可產品有望爲腫瘤患者提供新的治療選擇。本次合作可促進許可產品的研發,進一步豐富公司的產品管線,從而提升公司在腫瘤治療領域的綜合市場競爭力。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account